Dr. Ian Ganly, MD, PhD

Dr. Ganly practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.

Dr. Ganly's NPI, 1306868138, was assigned on July 24, 2006. Dr. Ganly graduated from University of Glasgow Faculty of Medicine in 1989. Dr. Ganly holds New York license 242698-1.

Dr. Ganly's primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.

Dr. Ganly's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. The medical group on file is Memorial Sloan Kettering Cancer Center. Dmand AI also links Dr. Ganly to 2 more group practices and clinics and 1 medical group, each named with a free account. Dr. Ganly's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ganly practices, 3 sites in all. Vendor and product names are available with a free account.

Otolaryngology is Dr. Ganly's primary specialty in the NPI Registry, under taxonomy code 207Y00000X. Dr. Ganly is licensed in New York.

Dmand AI lists endoscopic sinus surgery, larynx and vocal cord disease and thyroid surgery among the conditions Dr. Ganly treats.

CMS data shows 1,086 Medicare services from Dr. Ganly across 7 procedure codes in 2024, for 509 Medicare patients. Medicare paid $92,311 for them.

CMS counts 509 Medicare patients who saw Dr. Ganly in 2024. The largest group is 65 to 74, with 256 patients. 75% of them have high cholesterol, and 73% have high blood pressure. 9% are also on Medicaid. Their average risk score is 1.77, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Ganly's median patient age at 71, with 44% women.

In 2024, Dr. Ganly wrote 40 Medicare Part D claims for 25 patients. 85% of them were for generic drugs. CMS names the drug for 15 of them, across 1 drug with 11 or more claims each, at $522 in total drug cost. In 2023, CMS named 23 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 86 out of 100 for Dr. Ganly for performance year 2024, reported as part of a group. Dr. Ganly accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Ganly as offering telehealth. CMS counts 19 procedures of melanoma (skin cancer) excision by Dr. Ganly, more than 74% of the clinicians it reports for that procedure.

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

Upper gastrointestinal (GI) endoscopy for acid reflux: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 312 papers to Dr. Ganly, published from 2009 to 2025. 2021 was the busiest year, with 30. The most frequent topics are Thyroid Neoplasms, Carcinoma, Squamous Cell and Thyroidectomy. Dr. Ganly has published most often in Head Neck. Dr. Ganly's most frequent co-authors are Snehal G. Patel, MBBS, Jatin P. Shah, MD and Jatin Shah, MD.

Dmand AI links Dr. Ganly to 1 clinical trial. Conditions studied include Head and Neck Neoplasms.

CMS Open Payments shows 6 general payments to Dr. Ganly from 3 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 100% of the total. Medtronic, Inc. paid the most, $348.

Dr. Ganly graduated from University of Glasgow Faculty of Medicine in 1989.

Dr. Ganly is in network with 13 carriers, including Aetna, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.